Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribonucleic acid modulating drug candidates for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial that focuses on the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.
IPO Year:
Exchange: NASDAQ
Website: eloxxpharma.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/17/2021 | $4.00 | Outperform | Oppenheimer |
| 11/18/2021 | $2.00 → $1.00 | Neutral | HC Wainwright & Co. |
| 11/11/2021 | $3.00 → $2.00 | Neutral | HC Wainwright & Co. |
| 6/30/2021 | $3.10 | Buy | Mizuho |
Cognito Therapeutics, a pioneer developing disease-modifying therapeutics to treat CNS diseases, today announced the appointment of Greg Weaver as Chief Financial Officer (CFO), to lead all finance-related and investor relations functions at the Company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231017630946/en/Greg Weaver, CFO, Cognito Therapeutics (Photo: Business Wire) Mr. Weaver is a highly accomplished finance executive who brings more than 30 years of life sciences, financial and operations experience to Cognito. Most recently, he served as CFO of Atossa Therapeutics, Inc. (NASDAQ:ATOS), a clinical-stage oncology comp
SEATTLE, June 01, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet needs in oncology with a current focus on breast cancer, today announces the appointment of Greg Weaver as the Company's new Chief Financial Officer (CFO). Mr. Weaver succeeds Kyle Guse. A short video interview with Mr. Weaver about his background and vision for Atossa can be found here: https://youtu.be/G6ZzHLh-qsQ Mr. Weaver brings more than 30 years of life sciences, financial and operations experience to the Company. Recently, he served as CFO of privately held BioIntelliSense, a commerc
Lindsay Androski, JD, MBA brings significant experience growing biotech companies through her roles as an executive at Roivant Social Ventures Gadi Veinrib, Ran Nussbaum, Dr. Zafrira Avnur, Dr. Rajesh Parekh and Dr. Jasbir Seehra step down from the Eloxx board WATERTOWN, Mass., July 05, 2022 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced the appointment of Lindsay Androski, JD, MBA to its board of directors and as a member of the Board's Audit Committee and Compensation Committee. Current board members Gadi Veinrib, Ran Nussbaum, Dr. Zafrira Avnur, Dr. Rajesh Parekh and Dr.
WATERTOWN, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX), today announced the appointment of Ali Hariri, M.D., as its Chief Medical Officer, overseeing clinical development efforts for the company's promising pipeline of therapies to treat rare diseases. Dr. Hariri will report to Vijay Modur, M.B.B.S., Ph.D., the company's Head of Research and Development. Dr. Hariri was previously Senior Global Project Head in Rare Disease Clinical Development at Sanofi where he oversaw key functions responsible for advancing a number of investigational therapies along with full approval for on-market therapies within the Sanofi Genzyme specialty care business. Prior
Dr Alan E. Walts joins Hemogenyx Pharmaceuticals team; renowned business leader brings industry experience in corporate and private venture capital, business development, R&D and general management.LONDON, UK / ACCESSWIRE / July 26, 2021 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, announces the appointment of Dr Alan E. Walts as a Board observer and business advisor.Dr Walts is a US-based Venture Partner with Advent Life Sciences, a position he has held since January 2014. Dr Walts currently serves as a Director and audit committee member at Eloxx Pharmaceuticals (NASDAQ:ELOX), and as Executive Chairman o
SC 13D/A - Eloxx Pharmaceuticals, Inc. (0001035354) (Subject)
SC 13G/A - Eloxx Pharmaceuticals, Inc. (0001035354) (Subject)
SC 13G/A - Eloxx Pharmaceuticals, Inc. (0001035354) (Subject)
SC 13D/A - Eloxx Pharmaceuticals, Inc. (0001035354) (Subject)
SC 13G - Eloxx Pharmaceuticals, Inc. (0001035354) (Subject)
SC 13G - Eloxx Pharmaceuticals, Inc. (0001035354) (Subject)
SC 13D - Eloxx Pharmaceuticals, Inc. (0001035354) (Subject)
SC 13G/A - Eloxx Pharmaceuticals, Inc. (0001035354) (Subject)
Combination of subcutaneous ELX-02 with ivacaftor did not achieve statistical significance for efficacy endpoints in Phase 2 study in Class 1 CF ELX-02 was well tolerated with no drug-related serious adverse events observed Evidence of activity for ELX-02 observed; efficacy signal potentially confounded by variability due to low drug exposure Path forward for ELX-02 for the treatment of Class 1 CF to be determined together with CF Foundation Company to host conference call and webcast today, September 14, 2022, at 4:30 p.m. ET WATERTOWN, Mass., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare d
ELX-02 monotherapy dosed at 1.5mg/kg/day demonstrated a statistically significant 5.4mmol/L mean sweat chloride reduction, an established surrogate for restoration of CFTR biological activity ELX-02 monotherapy results support advancement of ELX-02 into Phase 3 clinical development First patient dosed in Phase 2 ELX-02 expansion treatment arms evaluating combination with ivacaftor; topline data expected by the end of the first half of 2022 Company to host conference call and webcast Wednesday, November 17, 2021 at 8:30 am ET WATERTOWN, Mass., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare dise
Combined Company to be Leader in Ribosomal RNA-Targeted Genetic Therapy Bringing Together Complementary Platforms Maximizes Potential for ELX-02 for Cystic Fibrosis in Phase 2 Development Adds Preclinical Stage Pipeline in Rare Diseases and Oncology Targeting RNA and Ribosomal Mutations Expects to File IND for First Oral Drug to Treat Patients with Recessive Dystrophic and Junctional Epidermolysis Bullosa (RDEB and JEB) Sumit Aggarwal, Zikani President and CEO, to Lead the Combined Company Eloxx to Issue Approximately 7.6 Million Shares to Zikani Stockholders Company to Host Investor Call at 8:30 a.m. ET, April 1 WALTHAM, Mass. and WATERTOWN, Mass., April 01, 2021 (GLOBE NEWSWIRE
Oppenheimer initiated coverage of Eloxx Pharmaceuticals with a rating of Outperform and set a new price target of $4.00
HC Wainwright & Co. reiterated coverage of Eloxx Pharmaceuticals with a rating of Neutral and set a new price target of $1.00 from $2.00 previously
HC Wainwright & Co. reiterated coverage of Eloxx Pharmaceuticals with a rating of Neutral and set a new price target of $2.00 from $3.00 previously
Mizuho initiated coverage of Eloxx Pharmaceuticals with a rating of Buy and set a new price target of $3.10
B. Riley Securities initiated coverage of Eloxx Pharmaceuticals with a rating of Buy and set a new price target of $5.00
NT 10-Q - Eloxx Pharmaceuticals, Inc. (0001035354) (Filer)
8-K - Eloxx Pharmaceuticals, Inc. (0001035354) (Filer)
NT 10-Q - Eloxx Pharmaceuticals, Inc. (0001035354) (Filer)
8-K - Eloxx Pharmaceuticals, Inc. (0001035354) (Filer)
NT 10-Q - Eloxx Pharmaceuticals, Inc. (0001035354) (Filer)
NT 10-K - Eloxx Pharmaceuticals, Inc. (0001035354) (Filer)
8-K - Eloxx Pharmaceuticals, Inc. (0001035354) (Filer)
8-K - Eloxx Pharmaceuticals, Inc. (0001035354) (Filer)
S-3 - Eloxx Pharmaceuticals, Inc. (0001035354) (Filer)
S-8 - Eloxx Pharmaceuticals, Inc. (0001035354) (Filer)
4 - Eloxx Pharmaceuticals, Inc. (0001035354) (Issuer)
4 - Eloxx Pharmaceuticals, Inc. (0001035354) (Issuer)
4 - Eloxx Pharmaceuticals, Inc. (0001035354) (Issuer)
4 - Eloxx Pharmaceuticals, Inc. (0001035354) (Issuer)
4 - Eloxx Pharmaceuticals, Inc. (0001035354) (Issuer)
4 - Eloxx Pharmaceuticals, Inc. (0001035354) (Issuer)
4 - Eloxx Pharmaceuticals, Inc. (0001035354) (Issuer)
4 - Eloxx Pharmaceuticals, Inc. (0001035354) (Issuer)
4 - Eloxx Pharmaceuticals, Inc. (0001035354) (Issuer)
4 - Eloxx Pharmaceuticals, Inc. (0001035354) (Issuer)
Data from Eloxx's proof-of-concept trial in patients with nonsense mutation Alport Syndrome (NMAS) presented in late-breaking presentation at American Society of Nephrology (ASN) Kidney Week New protein analyses confirm production of both collagen alpha 4 and collagen alpha 5 in patients post treatment with ELX-02 Results justify the need to conduct a larger clinical trial of ELX-02 in NMAS to confirm clinical benefit U.S. Food and Drug Administration (FDA) allows for continued dosing of subjects in Phase 1 trial of ZKN-013 WATERTOWN, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (OTC:ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases w
First two subjects dosed in Phase 1 clinical trial of ZKN-013; ZKN-013 is being developed for the potential treatment of rare dermatological and other diseases associated with nonsense mutations Positive written FDA feedback and guidance from a pre-Investigational New Drug Application (PIND) meeting provides pathway to IND application submission to initiate a Phase 2 clinical trial in the US with ELX-02 in patients with nonsense mutation alport syndrome (NMAS) Secured binding commitment for additional $3.2 million financing to advance our clinical programs WATERTOWN, Mass., July 11, 2024 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (OTC:ELOX), a leader in ribosomal RNA-targeted gene
ELX-02 Granted Orphan Drug Designation (ODD) from U.S. Food and Drug Administration (FDA) for Treatment of Alport Syndrome Pre-Investigational New Drug (IND) Meeting Requested with U.S. FDA for ELX-02 to Discuss Planned next Study In Nonsense Mutation Alport Syndrome Signed Global Licensing Partnership for ZKN-013 with Almirall Pharmaceuticals with $3M upfront and up to $470M in milestones and Tiered Royalties on Global Sales New Paper Published on Autosomal Dominant Polycystic Kidney Disease (ADPKD) shows that ELX-02 treatment prevents cyst formation in diseased PKD organoids with nonsense mutations and a single healthy gene copy WATERTOWN, Mass., April 16, 2024 (GLOBE NEWSWI
Almirall obtains exclusive global rights to develop and commercialize ZKN-013 for the treatment of rare dermatological and other diseases associated with nonsense mutationsZKN-013 is a phase I ready oral therapy designed to overcome nonsense mutations that cause a premature stop codon resulting in nonfunctional protein production for example in recessive Dystrophic Epidermolysis Bullosa (RDEB), Junctional Epidermolysis Bullosa (JEB) and familial adenomatous polyposis (FAP) BARCELONA, Spain and WATERTOWN, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Almirall, S.A. (BME:ALM) and Eloxx Pharmaceuticals, Inc. (OTC:ELOX) announced today that the companies have entered into an exclusive license agr
Almirall obtains exclusive global rights to develop and commercialize ZKN-013 for the treatment of rare dermatological and other diseases associated with nonsense mutations ZKN-013 is a phase I ready oral therapy designed to overcome nonsense mutations that cause a premature stop codon resulting in nonfunctional protein production for example in recessive Dystrophic Epidermolysis Bullosa (RDEB), Junctional Epidermolysis Bullosa (JEB) and familial adenomatous polyposis (FAP) Almirall, S.A. (BME:ALM) and Eloxx Pharmaceuticals, Inc. (OTC:ELOX) announced today that the companies have entered into an exclusive license agreement for the asset ZKN-013. Under the agreement, Almirall obtains
Kidney morphology improved in all three patients with protein re-expression consistent with disease regression in its Phase 2 open-label clinical trial of ELX-02 for the treatment of Alport Syndrome ELX-02 improved podocyte foot process effacement in all three treated patients by an average of 60% based on blinded biopsy analysis by NIPOKA GmbH Clinical data from Phase 2 study of ELX-02 for Alport Syndrome included in presentations at the American Society of Nephrology (ASN) Kidney Week 2023 Significant progress toward completion of a strategic partnership for ZKN-013 WATERTOWN, Mass., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (OTC:ELOX), a leader in ribosom
Cognito Therapeutics, a pioneer developing disease-modifying therapeutics to treat CNS diseases, today announced the appointment of Greg Weaver as Chief Financial Officer (CFO), to lead all finance-related and investor relations functions at the Company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231017630946/en/Greg Weaver, CFO, Cognito Therapeutics (Photo: Business Wire) Mr. Weaver is a highly accomplished finance executive who brings more than 30 years of life sciences, financial and operations experience to Cognito. Most recently, he served as CFO of Atossa Therapeutics, Inc. (NASDAQ:ATOS), a clinical-stage oncology comp
ELX-02 treatment improved podocyte foot process effacement in all three patients by an average of 60% based on a blinded kidney biopsy analysis by NIPOKA GmbH Biopsy results support clinical benefit in all three patients as improvement of kidney morphology is consistent with reduction or stabilization of proteinuria during or up to 2 months post completion of dosing Renowned key opinion leaders recommend continued development following review of clinical and biopsy results WATERTOWN, Mass., Oct. 09, 2023 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today reported results from an assessment of pat
WATERTOWN, Mass., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 380,590 of its shares of common stock (or common stock equivalents in lieu thereof) at a purchase price of $5.255 per share (or common stock equivalent in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, Eloxx has also agreed to issue and sell unregistered warrants to purchase up to an aggregate of 380,590 of its shares of common stock. The warra
Highly regarded renal pathologist and transmission electron microscopy (TEM) expert independently confirms previously reported qualitative assessment by Mayo Clinic of TEM biopsy scans All three patients treated with ELX-02 showed a visual improvement in podocyte foot process effacement post-treatment in kidney biopsies demonstrating the disease modifying effect of ELX-02 Podocyte foot process effacement is a hallmark of Alport syndrome Eloxx intends to gain alignment with U.S. Food and Drug Administration (FDA) on design of pivotal trial and potential for seeking Breakthrough Therapy Designation WATERTOWN, Mass., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ:E
Gainers Bellerophon Therapeutics (NASDAQ:BLPH) stock moved upwards by 17.1% to $0.12 during Friday's after-market session. Trading volume for this security closed at 2.1 million, accounting for 1394.7% of its average full-day volume over the last 100 days. The company's market cap stands at $1.4 million. Cingulate (NASDAQ:CING) stock increased by 12.59% to $0.58. The company's market cap stands at $10.0 million. Rain Oncology (NASDAQ:RAIN) stock rose 11.11% to $1.1. Rain Oncology's trading volume hit 98.3K shares by close, accounting for 45.0% of its average volume over the last 100 days. The company's market cap stands at $40.0 million. Artelo Biosciences (NASDAQ:ARTL) shares rose 9.72%
Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today reported results from an assessment of patient biopsies by NIPOKA GmbH (Nipoka). They have developed a highly accurate method for the quantification of podocyte foot process morphology. These results confirm previously reported positive biopsy results from the proof-of-concept Phase 2 open-label clinical trial (NCT05448755) of ELX-02 for the treatment of Nonsense Mutation Alport syndrome patients. Analysis of formalin-fixed paraffin-embedded (FFPE) biopsy samples by Nipoka show ELX-02 treatment improved podocyte foot process morphology with lower effacement in all three pa
Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 380,590 of its shares of common stock (or common stock equivalents in lieu thereof) at a purchase price of $5.255 per share (or common stock equivalent in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, Eloxx has also agreed to issue and sell unregistered warrants to purchase up to an aggregate of 380,590 of its shares of common stock. The warrants will have an exercise price $5.13 per share, will b
Gainers First Wave BioPharma (NASDAQ:FWBI) shares moved upwards by 23.8% to $0.54 during Thursday's regular session. As of 13:30 EST, this security is trading at a volume of 121.0 million shares, making up 4158.0% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $3.8 million. Synlogic (NASDAQ:SYBX) stock moved upwards by 23.67% to $0.3. The current volume of 316.6K shares is 163.6% of Synlogic's average full-day volume over the last 100 days (last updated at 13:30 EST). The company's market cap stands at $20.9 million. ENDRA Life Sciences (NASDAQ:NDRA) stock moved upwards by 22.79% to $1.25. Trading volume for ENDRA Life Sciences's
Investigational New Drug (IND) application submitted to U.S. Food and Drug Administration (FDA) for ELX-02 for the treatment of Alport syndrome with nonsense mutations Rebound in average UPCR 3-months post treatment provides further evidence that proteinuria remission in one out of three patients was drug relatedAll 3 Alport patients (100% response rate) treated with ELX-02 had biopsy confirmed disease regression, suggesting clinical benefit likely with longer treatment durationSignificant strategic interest in ZKN-013 following FDA approval to start Phase 1 single ascending dose (SAD) trial
Gainers Novo Integrated Sciences (NASDAQ:NVOS) stock moved upwards by 23.5% to $0.14 during Tuesday's after-market session. This security traded at a volume of 29.7 million shares come close, making up 590.5% of its average volume over the last 100 days. The company's market cap stands at $21.2 million. Nexalin Technology (NASDAQ:NXL) stock increased by 17.82% to $0.72. The market value of their outstanding shares is at $5.2 million. As per the news, the Q2 earnings report came out 3 days ago. T2 Biosystems (NASDAQ:TTOO) shares moved upwards by 14.7% to $0.68. Today's trading volume for this security ended up closing at 38.1 million shares, which is 43.5 percent of its average volume over
Gainers Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) shares jumped 283.7% to $1.3007 after Harmony Biosciences entered into definitive agreement to acquire the company for total potential consideration of up to $200 million in cash. Taysha Gene Therapies, Inc. (NASDAQ:TSHA) gained 96.1% to $1.4488 after the company reported initial clinical data from first adult Rett syndrome patient dosed in REVEAL Phase 1/2 trial. The company also announced second-quarter results. Hanryu Holdings, Inc. (NASDAQ:HRYU) climbed 37.9% to $6.44. Hanryu Holdings partnered with SALTLUX for the development of AI powered conversational virtual assistant on popular K-Culture fandom application, FANTOO. TMC the
Eloxx Pharmaceuticals (NASDAQ:ELOX) reported quarterly losses of $(1.96) per share which missed the analyst consensus estimate of $(1.54) by 27.27 percent. This is a 1533.33 percent decrease over losses of $(0.12) per share from the same period last year.
Gainers AGBA Group Holding Limited (NASDAQ:AGBA) shares surged 49.4% to $1.31 in pre-market trading after the company reported a 325% year-over-year growth in its second-quarter revenue. AMC Entertainment Hldg Pref Equity Units (NYSE:APE) rose 29.8% to $2.31 in pre-market trading after AMC gained court approval for its revised stock conversion plan. Proterra Inc. (NASDAQ:PTRA) shares gained 25.2% to $0.1483 in pre-market trading on continued volatility after the company announced it filed for Chapter 11 bankruptcy. United States Steel Corporation (NYSE:X) shares rose 23% to $27.95 in pre-market trading. United States Steel late Sunday rejected a buyout offer from rival steel manufactu